bluuebunny/crossref_metadata_2025_split huggingface dataset:
Association between Health Literacy and Self-care Behaviors with Traditional Thai Medicine during the COVID-19 Pandemic
Authors: Silangirn Pongsaton , Thummayot Sarinthorn , Sadjapong Uratcha , Thongtip Sakesun 
Published: July 2024

Background
Health literacy is a multidimensional concept that can lead to changing self-care behaviors.

Objective
This study aimed to assess health literacy, self-care behaviors, and factors related to self-care behaviors in traditional Thai medicine during the COVID-19 pandemic.

Methods
This cross-sectional study included 422 participants. The questionnaire consisted of sociodemographic characteristics, health literacy of traditional Thai medicine with COVID-19, and self-care behavior with traditional Thai medicine in relation to COVID-19. The data were analyzed using descriptive statistics, independent-sample test, one-way ANOVA, and Pearson's correlation coefficient.

Results
The mean score for communication to promote health was high (34.6±8.4). The mean score of overall health literacy was moderate (156.8±20.7), followed by self-care behavior (45.6±6.0), access to health information and services (30.5±5.2), and health knowledge and understanding (26.7±2.6). Pearson correlation coefficient analysis showed that there were significantly positive self-care behaviors, namely, access to health information and services (P-value < 0.001), communication to promote health (P-value < 0.001), media and information literacy (P-value < 0.043), and overall health literacy (P-value < 0.003), while informed decision-making was significantly negatively associated with self-care behaviors (P-value < 0.004).

Conclusion
Increasing overall health literacy and each dimension was associated with self-care behaviors. The findings suggest that interventional programs to develop health literacy are required to improve self-care behaviors.
1245-P: GDM Patients and Prognostic Factors for Subsequent Type 2 Diabetes Mellitus—An Electronic Cohort Review
Authors: KIM RYUNG S. , LI LIHUA , ISASI CARMEN R. , PHILIS-TSIMIKAS ATHENA , MOON JEE-YOUNG , LIU JUNXIU , WOLFE DIANA S. , LEVY CAROL J. 
Published: July 2024

Introduction: GDM affects 8-10% of pregnancies in the US and nearly 50% of these women have subsequent diabetes diagnosis. However, research on the prognostic factors of T2D incidence among women with GDM is scarce, due to the limited sample sizes. We aim 1) to construct a large electronic cohort of GDM and 2) to build a prognostic model for T2D incidence among patients with GDM.
Methods: We extracted EMRs of patients diagnosed with GDM between 2016 and 2022 from two health systems in NYC: Montefiore (MMC) and Mt. Sinai. Only MMC patients were analyzed in this report. Prognostic factors during pregnancy included 32 baseline & pregnancy characteristics, 76 office visit variables, 418 lab tests, and prescription of 31 drugs. Time from GDM diagnosis to T2D was analyzed using proportional hazards models.
Results: We collected EMRs of 6,014 GDM patients at MMC who were racially diverse with a median age of 32, BMI of 31.8 kg/m2. Among them, 355 (5.9%) later developed T2D, yielding a high T2D incidence rate (21.1 per 1,000 PY). There was an immediate heightened risk: T2D incidence proportions were 3.8% by 1 year after GDM diagnosis, and 11.9% by 5 years. The risk was elevated in Hispanic White (HR=2.3), Hispanic Non-White (HR=2.0), and Black (HR=2.3) compared to non-Hispanic White (p&lt;0.00001). The risk was associated with higher BMI during pregnancy, insulin or oral-agent control compared to diet therapy, younger gestational age at GDM diagnosis, and Caesarean delivery. Lab findings associated with T2D risk included maternal glucose levels, erythrocyte MCH, monocytes, and ketone. T2D incidence was also associated with prescription of insulin therapy, oral treatment, aspirin, and iron supplements likely indicating underlying obstetric complications.
Conclusions: A large electronic cohort of GDM patients identified potential prognostic factors of subsequent T2D. Future directions include calibration of 2 cohorts to establish the largest electronic cohort of GDM to date and building prognostic models for T2D risk.

Disclosure
R.S. Kim: None. L. Li: None. C.R. Isasi: None. A. Philis-Tsimikas: Advisory Panel; Dexcom, Inc., Lilly Diabetes, Novo Nordisk, Sanofi, Medtronic, Bayer Inc. J. Moon: None. J. Liu: None. D.S. Wolfe: None. C.J. Levy: Research Support; Dexcom, Inc. Consultant; Dexcom, Inc. Research Support; MannKind Corporation, T1D Exchange, Tandem Diabetes Care, Inc., Abbott, Insulet Corporation.

Funding
New York Regional Center for Diabetes Translation Research Pilot & Feasibility Project
1308-P: A Voice-Based AI Algorithm Can Predict Type 2 Diabetes Status—Findings from the Colive Voice Study on U.S. Adult Participants
Authors: ELBEJI ABIR , PIZZIMENTI MÉGANE , AGUAYO GLORIA A. , FISCHER AURELIE , AYADI HANIN , MAUVAIS-JARVIS FRANCK , RIVELINE JEAN-PIERRE , DESPOTOVIC VLADIMIR , FAGHERAZZI GUY 
Published: July 2024

Introduction: Reducing undiagnosed type 2 diabetes (T2D) cases worldwide is an urgent public health challenge. Most current screening methods are invasive, lab-based, and costly. Meanwhile, there is a growing focus on noninvasive T2D detection through advanced artificial intelligence (AI) and digital technology. This study explores the feasibility of using a voice-based AI algorithm to predict T2D status in adults, a preliminary step toward innovative screening tools.
Objective: To develop and assess the performance of a voice-based AI algorithm for T2D status detection in the adult population in the US.
Methods: We analyzed text reading voice recordings from 607 US participants from the Colive Voice study, adhering to the CONSORT AI standards. We trained and cross-validated algorithms with BYOL-S/CvT embeddings for each gender, evaluating them on accuracy, precision, recall, and AUC. Performance of the best models was stratified by age, BMI, and hypertension, and compared to the American Diabetes Association (ADA) score for T2D risk assessment using a Bland-Altman analysis.
Results: We analyzed 323 females and 284 males; Females with T2D (age: 49.5 years, BMI: 35.8 kg/m²) vs without (40.0 years, 28.0 kg/m²). Males with T2D (47.6 years, 32.8 kg/m²) vs without (41.6 years, 26.6 kg/m²). The voice-based algorithm achieved good overall predictive capacity (AUC=75% for males, 71% for females) and correctly predicted 71% of male and 66% of female T2D cases. It is enhanced in females aged 60 years (AUC=74%) or older but also with the presence of hypertension for both genders (AUC=75%). We observed an overall agreement above 93% with the ADA risk score.
Conclusion: This study demonstrates the feasibility of detecting T2D using exclusively voice features. It is the first step toward using voice analysis as a first-line T2D screening strategy. While the findings are promising, further research and validation are necessary to specifically target early-stage T2D cases.

Disclosure
A. Elbeji: None. M. Pizzimenti: None. G.A. Aguayo: None. A. Fischer: None. H. Ayadi: None. F. Mauvais-Jarvis: None. J. Riveline: Board Member; Abbott, Novo Nordisk A/S, Sanofi, Eli Lilly and Company, Medtronic, Dexcom, Inc., Insulet Corporation, Air Liquide, AstraZeneca. V. Despotovic: None. G. Fagherazzi: Speaker's Bureau; Sanofi. Advisory Panel; Timkl, SAB Biotherapeutics, Inc., Vitalaire, Roche Diabetes Care.
138-OR: Pioglitazone Amplifies the Decrease in HbA1c and Prevents the Increase in Plasma Ketone Caused by Dapagliflozin in Type 1 Diabetes Mellitus Patients
Authors: ABDUL-GHANI MUHAMMAD , BASKOY GOZDE , NAKHLEH AFIF , ABDELGANI SIHAM , AL-MULLA FAHD , ABU-FARHA MOHAMED , ALAJMI FAHAD , ALESSA THAMER , DEFRONZO RALPH A. , SHEHADEH NAIM 
Published: July 2024

Introduction and Objectives: SGLT2 inhibitors (SGLT2i) lower the plasma glucose concentration in T1DM patients. However, they cause an increase in plasma ketone concentration and risk of ketoacidosis. The aim of the present study is to examine whether pioglitazone amplifies the decrease in HbA1c and prevents the increase in plasma ketone concentration caused by dapagliflozin in T1DM patients.
Methods: After a 4-week run in period, 60 T1DM patients received dapagliflozin 10 mg for 12 weeks. At week 16 patients were randomized to receive in double blind fashion pioglitazone (45 mg) or matching placebo for an additional 16 weeks.
Results: T1DM patients were 42±3 years of age, 30% female, BMI=26.8±0.7, HbA1c=8.5±0.2%, insulin dose= 63±4 units, and eGFR=114±6 ml/min. Dapagliflozin caused -0.63±0.18%, and -0.56±0.11% decrease from baseline in HbA1c at week 16 in subjects receiving pioglitazone and placebo, respectively (both p&lt;0.001). At week 32, the decrease from baseline in HbA1c was -0.86±0.3 and -0.44±0.17 in subjects receiving pioglitazone and placebo, respectively. Thus, the HbA1c was -0.42±0.12 lower in subjects receiving pioglitazone versus placebo (p&lt;0.05). Plasma ketone concentration increased above baseline by 0.12±0.03 mM and 0.14±0.03 mM at week 16 in subjects receiving pioglitazone and placebo, respectively (both p&lt;0.05). At week 32 plasma ketone concentration remained elevated above baseline in subjects receiving placebo (0.15±0.03 mM, p&lt;0.05), and decreased below baseline (-0.06±0.02mM, p&lt;0.05) in subjects receiving pioglitazone. Thus, the difference in plasma ketone concentration between subjects receiving pioglitazone and placebo at week 32 was -0.19±0.3, p&lt;0.001.
Conclusion: Addition of pioglitazone to SGLT2i in T1DM patients amplifies the decrease in HbA1c and prevents the increase in plasma ketone caused by SGLT2i, allowing long-term cardiovascular and renal outcome studies to be carried out safely in T1DM patients.

Disclosure
M. Abdul-Ghani: None. G. Baskoy: None. A. Nakhleh: None. S. Abdelgani: None. F. Al-Mulla: None. M. Abu-farha: None. F. Alajmi: Consultant; Novo Nordisk. Research Support; Novo Nordisk. Speaker's Bureau; Novo Nordisk. T. Alessa: None. R.A. DeFronzo: Advisory Panel; AstraZeneca, Novo Nordisk, Boehringer-Ingelheim, Intarcia Therapeutics, Inc., Aardvark, Renalytix, Corcept Therapeutics, Alnylam Pharmaceuticals, Inc. Research Support; Boehringer-Ingelheim, AstraZeneca, 89bio, Inc., Amgen Inc., Medality, Corcept Therapeutics. Speaker's Bureau; AstraZeneca, Corcept Therapeutics, Renalytix. N. Shehadeh: Research Support; Abbott. Advisory Panel; AstraZeneca, Eli Lilly and Company, Boehringer-Ingelheim. Research Support; Novo Nordisk Foundation.

Funding
The study was funded by JDRF grant to MAG. Astrazeneca provided dapagliflozin.
229-OR: Orforglipron Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes
Authors: ROSENSTOCK JULIO , ROBINS DEBORAH A. , DUFFIN KEVIN L. , WILSON JONATHAN M. , MATHER KIEREN J. , BANERJEE HIYA , LIN YANZHU , EYDE SARAH , KAZDA CHRISTOF M. , KONIG MANIGE 
Published: July 2024

Orforglipron (OFG), an oral, non-peptide GLP-1 receptor agonist, demonstrated significantly greater glycemic control and weight loss at doses ≥12 mg vs placebo (PBO) or dulaglutide (DU) 1.5 mg in a 26-week phase 2 study of adults with type 2 diabetes (T2D) (Table). These exploratory analyses investigated mechanisms by which OFG improved glycemic control in T2D by analyzing exploratory biomarkers.
Participants with T2D (mean age, 58.9 years; baseline HbA1c, 8.1%; weight, 100.3 kg) treated with diet and exercise, with/without metformin, were randomized to PBO, DU 1.5 mg, or once-daily OFG 3, 12, 24, 36, or 45 mg. Biomarkers of β-cell function and insulin sensitivity were analyzed by mixed model repeated measures, excluding data after study drug discontinuation or rescue drug initiation.
Biomarkers of β-cell function were improved by OFG at 26 weeks from baseline (Table). HOMA-B significantly increased with OFG at doses ≥12 mg vs PBO or DU. HOMA-IR (computed with insulin) significantly decreased from baseline with OFG at doses ≥24 mg but was not significantly different vs PBO and DU. Fasting glucose-adjusted glucagon significantly decreased with OFG at doses ≥12 mg vs PBO and with OFG 12, 24, and 45 mg vs DU.
These analyses suggest improved glycemic control with OFG vs DU may be partly explained by improved β-cell function and insulin sensitivity. Additional studies are ongoing to understand these mechanisms.

Disclosure
J. Rosenstock: Research Support; Biomea Fusion, Inc. Other Relationship; Lilly Diabetes. Research Support; Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Corcept Therapeutics. Other Relationship; Novo Nordisk. Research Support; Pfizer Inc. Other Relationship; Sanofi, Boehringer-Ingelheim. Research Support; Shionogi & Co., Ltd. Other Relationship; Structure Therapeutics, Inc. Advisory Panel; Terns Pharmaceuticals, Zealand Pharma A/S. Other Relationship; Applied Therapeutics, Hanmi Pharm. Co., Ltd., Oramed Pharmaceuticals. Advisory Panel; Scholar Rock. D.A. Robins: None. K.L. Duffin: Employee; Eli Lilly and Company. J.M. Wilson: Employee; Eli Lilly and Company. K.J. Mather: Employee; Eli Lilly and Company. H. Banerjee: None. Y. Lin: Stock/Shareholder; Eli Lilly and Company, Pfizer Inc., AstraZeneca. S. Eyde: None. C.M. Kazda: Employee; Eli Lilly and Company. M. Konig: None.

Funding
Eli Lilly and Company
344-OR: The MOTS-c/CK2 Pathway Is a Novel Molecular Target for Type 2 Diabetes in East Asians
Authors: KUMAGAI HIROSHI , JEONG KIM SU , MILLER BRENDAN , HYUNG LEE SHIN , ZEMPO HIROFUMI , NATSUME TOSHIHARU , WAN JUNXIANG , RAMIREZ RICARDO , MEHTA HEMAL H. , NISHIDA YUICHIRO , FUKU NORIYUKI , DOBASHI SHOHEI , MIYAMOTO-MIKAMI ERI , NAITO HISASHI , HARA MEGUMI , IWASAKA CHIHARU , YAMADA YOSUKE , HIGAKI YASUKI , TANAKA KEITARO , YEN KELVIN , COHEN PINCHAS 
Published: July 2024

Introduction & Objective: MOTS-c is a mitochondrial DNA-encoded microprotein that improves impaired glucose metabolism caused by aging and high fat diet. The presence of a naturally occurring genetic variant of MOTS-c, K14Q MOTS-c, increases the susceptibility to type 2 diabetes (T2D) in East Asians. Nevertheless, the precise mechanism of MOTS-c action has not been fully elucidated. Here, we demonstrate that the protein kinase CK2 is a functional and direct target of MOTS-c and that the reduced binding of K14Q MOTS-c to CK2 increases the risk of T2D.
Methods: We performed in vitro experiments, including dot blot, kinase activity, and surface plasmon resonance assays, to investigate the direct interaction between MOTS-c and CK2. We also examined the impact of MOTS-c treatment on CK2 activity in skeletal muscle, as well as on muscle glucose uptake in young mice. Subsequently, we investigated the impact of a naturally occurring K14Q MOTS-c variant on the prevalence of T2D in 12,068 Japanese individuals.
Results: Dot blot and cell-free kinase activity assays demonstrated that MOTS-c activated CK2 by binding directly to its α subunit, and this binding was confirmed using a surface plasmon resonance assay. Importantly, the binding affinity of K14Q MOTS-c to CK2α was 16-fold less than that of the wild type MOTS-c, and K14Q MOTS-c did not activate CK2 in the cell-free kinase activity assay. Skeletal muscle CK2 activity was lower in old mice and higher after exercise, and was increased by MOTS-c administration, but not K14Q MOTS-c. MOTS-c administration, but not K14Q MOTS-c, significantly enhanced muscle glucose uptake, which was blunted by a CK2 inhibitor. In humans, the K14Q MOTS-c carriers exhibited an increased risk of type 2 diabetes, particularly among individuals aged 60 and above, while this increased risk was mitigated by daily physical activity.
Conclusion: Together, these findings provide evidence that CK2 is required for MOTS-c effects and that the MOTS-c/CK2 pathway is a potential therapeutic target for T2D.&lt;u&gt;&lt;/u&gt;

Disclosure
H. Kumagai: None. S. Kim: None. B. Miller: None. S. Lee: None. H. Zempo: None. T. Natsume: None. J. Wan: None. R. Ramirez II: None. H.H. Mehta: None. Y. Nishida: None. N. Fuku: None. S. Dobashi: None. E. Miyamoto-Mikami: None. H. Naito: None. M. Hara: None. C. Iwasaka: None. Y. Yamada: None. Y. Higaki: None. K. Tanaka: None. K. Yen: None. P. Cohen: None.
348-OR: Multiancestry Whole Genome Sequencing (WGS) Meta-analysis to Identify Loci Associated with Imaging-Measured Hepatic Steatosis
Authors: ALLRED NICHOLETTE , RAUT CHINMAY , CHEN YANHUA , OLIVERI ANTONINO , O'CONNELL JEFFREY , RYAN KATHLEEN , ROTTER JEROME I. , RICH STEPHEN S. , HAKIM AARON , PEYSER PATRICIA , BIELAK LAWRENCE F. , LIU CHING-TI , TERRY JAMES G. , FORNAGE MYRIAM , WAGENKNECHT LYNNE E. , SPELIOTES ELIZABETH K. , TRANS-OMICS FOR PRECISION MEDICINE (TOPMED)PROGRAM NHLBI , CONSORTIUM GOLD 
Published: July 2024

Introduction and Objective: Steatotic liver disease, formerly called non-alcoholic fatty liver disease (NAFLD), is the most common cause of chronic liver disease worldwide; yet, few effective methods for prevention/treatment exist making it one of the biggest unmet public health needs of our time. To date, genetic studies have been limited to identifying common variants in predominantly European-ancestry populations or focused on surrogate phenotypes, e.g. liver enzymes, identifying association with comorbidities. Here we present a multi-ancestry whole genome sequencing (WGS) association study to discover rare variants associated with imaging-measured hepatic steatosis.
Methods: Study-, ancestry- and sex-stratified association analyses were conducted using SAIGEgds in nine studies with imaging-measured hepatic steatosis adjusted for age, sex, alcoholic drinks per week and principal component estimates of admixture. Stratified results were meta-analyzed using a fixed-effects model. Cochran’s Q-test and the I2 metric were used to estimate heterogeneity.
Results: Meta-analyses included 23,156 European, African, Hispanic and Chinese ancestry individuals and identified five significant loci (P&lt;5x10-08): PNPLA3, PPP1R3B, HAPLN4, intergenic region on chr14 and F11-AS1. Nine additional variants trended toward association (P&lt;5x10-07). Sex-stratified meta-analyses revealed additional associations in an intergenic region on chr10, RP11-115J16.1 and UBE3B. Variants in RP11-115J16.1 remained significant in European ancestry samples. Significantly associated variants in SLC2A1-AS1 and LINC01684 were novel loci in African Americans.
Conclusion: Taken together, multi-ancestry analysis of imaging-measured hepatic steatosis using WGS replicated previously associated loci and identified novel sex- and ancestry-specific loci. Functional studies are underway to determine the biological impact of these findings.

Disclosure
N. Allred: None. C. Raut: None. Y. Chen: None. A. Oliveri: None. J. O'Connell: None. K. Ryan: None. J.I. Rotter: None. S.S. Rich: None. A. Hakim: None. P. Peyser: None. L.F. Bielak: None. C. Liu: None. J.G. Terry: None. M. Fornage: None. L.E. Wagenknecht: None. E.K. Speliotes: Other Relationship; University of Michigan.

Funding
National Institute of Diabetes and Digestive Kidney Disease (R01 DK128871)
Sitting Time and Its Interaction With Physical Activity in Relation to All-Cause and Heart Disease Mortality in U.S. Adults With Diabetes
Authors: Dai Wen , Albrecht Sandra S. 
Published: July 2024

OBJECTIVE
To evaluate whether associations between sitting time and all-cause and heart disease mortality are modified by physical activity in adults with diabetes.

RESEARCH DESIGN AND METHODS
Data came from 6,335 U.S. adults with diabetes from National Health and Nutrition Examination Survey 2007–2018 (baseline), with mortality follow-up through 2019. Sitting time and moderate to vigorous physical activity (MVPA) were self-reported. Cox models were adjusted for sociodemographics, lifestyle factors, and medical conditions.

RESULTS
Over a median follow-up of 5.9 years, 1,278 all-cause and 354 heart disease deaths were documented (mean age, 59.6 years; 48.3% female). Longer sitting time was associated with greater all-cause and heart disease mortality risk in inactive (MVPA &lt;10 min/week) or insufficiently active (MVPA 10 to &lt;150 min/week) adults with diabetes, but not in active adults (MVPA ≥150 min/week) (all-cause mortality: P = 0.003 for interaction; heart disease mortality: P = 0.008 for interaction).

CONCLUSIONS
In adults with diabetes, meeting guideline-recommended physical activity may offset the elevated all-cause and heart disease mortality risk associated with excessive sitting time.
Surrealismo ao New Queer Cinema
Authors: Cardoso Alexandre 
Published: July 2024

Estendendo-se da literatura à fotografia e às artes plásticas e, mais tardiamente, ao cinema, o surrealismo revolucionou de maneira impressionante a linguagem clássica das artes. De fato, como se sabe, desde os alvores do século passado, o movimento introduziu seus singulares métodos de montagem e sua filosofia própria nas estruturas narrativas desses diferentes domínios estéticos, em honra do reconhecimento das manifestações do inconsciente. Diante disso, o objetivo do presente artigo é não apenas reapresentar o movimento, em sua conexão com a psicanálise, mas valer-se da própria revolução psicanalítica, com sua teorização da ambiguidade sexual, para examinar a questão dos gêneros e das posições sexuais no seio de uma cinematografia de risco mas não obstante marcada pela assinatura masculina e pela cisheteronormatividade.
Objects of Legal Relationships: Sector-Specific Approach
Authors: Ivanova S. V. 
Published: July 2024

Introduction. The object of legal relationship is an important element of any legal relations. This is due to the fact that no legal relationship can take place if there is no an object. In the doctrine of law, the essence of an object of legal relationship is under dispute. As a result of doctrinal research, the monistic and pluralistic concepts have been formulated in the legal literature. The aim of this article is to study the theoretical provisions for the object of legal relationship and develop practical recommendations on amending the current legislation. Based on the provisions of the object of legal relationship concepts existing in the doctrine of law, the author investigates the specific features of the legal relationship objects of the animal world protection and use. Nowadays the study of the objects of faunistic legal relationships is relevant due to importance of the animal world objects for the society and state, because in the process of rights and liabilities fulfilment, the subjects of legal relationships satisfy the economic, environmental and social interests.Materials and Methods. In the article, the methodological basis is formed by a set of philosophical, general scientific and specific scientific methods of cognition (analysis, synthesis, concrete-historical, logical methods, etc.).The Results. Formulating the practical recommendations for amending the current animal welfare legislation is claimed to be the research result. The article differentiates the regulation of the faunistic and civil legal relationships.Discussion and Conclusion. The article could be used in the educational activities of law universities and faculties, as well as in the activities of the executive authorities of the Russian Federation subjects. The author has provided the definition of a juridical and material objects of faunistic legal relationship and examined the differences and features thereof. To fill in the gaps in legislation, the author has proposed to develop and adopt the regulatory legal acts within the jurisdiction of the subjects of the Russian Federation aimed at regulating the relationships on the use of the wild animals not classified as hunting and fishing resources. The author has drawn the conclusion on the necessity to include CITES species and derivatives into the current animal welfare legislation. The theoretical and practical conclusions made by the author could be taken into account for further study of the specifics of the faunistic legal relationship.